Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
Janux Therapeutics, Inc. (JANX) had Free Cash Flow of $-41.68M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-33.86M |
|
-- |
|
-- |
|
$45.12M |
|
$-45.12M |
|
$11.26M |
|
$-33.86M |
|
$-33.86M |
|
$-33.86M |
|
$-33.86M |
|
$-33.86M |
|
$-33.86M |
|
$-45.12M |
|
$-49.78M |
|
61.90M |
|
61.90M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$1.01B |
|
$4.69M |
|
$26.66M |
|
$1.03B |
|
$21.38M |
|
-- |
|
$20.32M |
|
$41.70M |
|
$990.52M |
|
$990.52M |
|
$990.52M |
|
59.30M |
|
| Cash Flow Statement Financials | |
$-40.84M |
|
$-338.83M |
|
$1.51M |
|
$431.42M |
|
$53.26M |
|
$-378.16M |
|
$21.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
47.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Free Cash Flow |
$-41.68M |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-3.42% |
|
-3.42% |
|
-3.28% |
|
-3.42% |
|
$16.70 |
|
$-0.67 |
|
$-0.66 |
|